Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Rises By 85.8%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 50,900 shares, an increase of 85.8% from the October 15th total of 27,400 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average daily trading volume, of 44,500 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by institutional investors.

Avenue Therapeutics Price Performance

Shares of NASDAQ ATXI traded up $0.05 during mid-day trading on Friday, reaching $1.93. 106,413 shares of the company’s stock traded hands, compared to its average volume of 60,642. The business has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $3.00. The stock has a market cap of $2.76 million, a P/E ratio of 0.06 and a beta of -0.17. Avenue Therapeutics has a 1-year low of $1.60 and a 1-year high of $26.47.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.